title: Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor.
abstract: Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors. It is known that many cases ultimately acquired resistance to crizotinib. However, a case of primary resistance is rare. We present a case of harboring exon 19 deletion in epidermal growth factor receptor in ALK rearranged lung adenocarcinoma, who experienced a partial tumor response to icotinib after failure with crizotinib therapy and chemotherapy. Considering the partial response, we conclude that it is important to find the cause of resistance to crizotinib. We detected gene mutations with plasma by the next-generation sequencing; the next-generation sequencing demonstrates an attractive system to identify mutations improving the outcome of patients with a deadly disease.
authors.affiliation: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
authors.forename: Wenxian
authors.initials: W
authors.lastname: Wang
authors.affiliation: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Jiang
authors.affiliation: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China.
authors.forename: Zhengbo
authors.initials: Z
authors.lastname: Song
authors.affiliation: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China.
authors.forename: Yiping
authors.initials: Y
authors.lastname: Zhang
keywords: anaplastic lymphoma kinase; crizotinib; epidermal growth factor receptor; non-small cell lung cancer
references.citation: Lung Cancer. 2014 Nov;86(2):207-12
references.pmid: 25261231
references.citation: Lancet Oncol. 2014 Sep;15(10):1119-28
references.pmid: 25153538
references.citation: Genes Chromosomes Cancer. 2013 May;52(5):503-11
references.pmid: 23362162
references.citation: N Engl J Med. 2010 Oct 28;363(18):1734-9
references.pmid: 20979473
references.citation: J Natl Compr Canc Netw. 2015 May;13(5):515-24
references.pmid: 25964637
references.citation: Nat Rev Clin Oncol. 2012 Apr 03;9(5):268-77
references.pmid: 22473102
references.citation: Clin Cancer Res. 2012 Mar 1;18(5):1472-82
references.pmid: 22235099
references.citation: Lancet Oncol. 2011 Oct;12(11):1004-12
references.pmid: 21933749
references.citation: Sci Transl Med. 2012 Feb 8;4(120):120ra17
references.pmid: 22277784
references.citation: N Engl J Med. 2014 Mar 27;370(13):1189-97
references.pmid: 24670165
references.citation: Oncologist. 2015 Mar;20(3):316-22
references.pmid: 25721120
references.citation: Pharmacogenomics. 2012 May;13(7):789-802
references.pmid: 22594511
references.citation: J Exp Clin Cancer Res. 2010 Oct 06;29:132
references.pmid: 20925915
references.citation: Oncol Res Treat. 2015;38(6):291-8
references.pmid: 26045026